Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Subthalamic Nucleus (STN)-Targeted Transcranial Temporal Interference Stimulation (TIS) for Parkinson's Disease: Efficacy and Safety From a Single-Center, Prospective, Double-Blind Randomized Controlled Trial

NCT: NCT07361250 · COMPLETED

NCT IDNCT07361250
StatusCOMPLETED
Start Date2026-01-20
Completion2026-06-20
SponsorTang Zhouping (OTHER)
First posted
Last updated

Brief Summary

This is a single-center, prospective, double-blind, randomized controlled trial to evaluate the efficacy and safety of transcranial temporal interference stimulation targeting the subthalamic nucleus in patients with Parkinson's disease. It plans to enroll 20 eligible participants who will be randomly assigned in a 1:1 ratio to either the active TIS stimulation group or the sham stimulation group.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑